Aarti Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
October 19, 2023 at 06:34 am EDT
Share
Aarti Drugs Limited reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported sales was INR 6,415.4 million compared to INR 6,877.2 million a year ago. Revenue was INR 6,422.2 million compared to INR 6,877.8 million a year ago. Net income was INR 395.9 million compared to INR 387.5 million a year ago. Basic earnings per share from continuing operations was INR 4.29 compared to INR 4.18 a year ago. Diluted earnings per share from continuing operations was INR 4.29 compared to INR 4.18 a year ago.
For the six months, sales was INR 13,026.4 million compared to INR 13,096.8 million a year ago. Revenue was INR 13,039.3 million compared to INR 13,100 million a year ago. Net income was INR 874.4 million compared to INR 735.4 million a year ago. Basic earnings per share from continuing operations was INR 9.47 compared to INR 7.94 a year ago. Diluted earnings per share from continuing operations was INR 9.47 compared to INR 7.94 a year ago.
Aarti Drugs Limited is an India-based company that is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.
AARTI DRUGS LIMITED 
